Chondroitin Sulfate
Glycosaminoglycan found in cartilage. Often combined with glucosamine for joint health. Helps retain water in cartilage and inhibits degradative enzymes.
Projected serum levels — 800 mg, once daily
Maintenance schedule: 800 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 60.5 mg, trough ≈ 3.1 mg body load. Population-based estimate over 15 days for a 800 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Joint Support
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 4.9 h
- Common dose
- 800 mg
- Suggested maximum
- 1.2k mg/day
- Reference dose range
- 400–1.2k mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Chondroitin for osteoarthritis
Cochrane review of 43 RCTs found chondroitin (alone or combined with glucosamine) provided small-to-moderate improvement in joint pain and function in osteoarthritis.
-
Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
Large multicenter RCT of 622 patients found chondroitin sulfate (800 mg/day for 2 years) significantly reduced joint space loss and improved pain compared to placebo.
-
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis
Meta-analysis found chondroitin significantly reduced joint space narrowing (structure modification) and improved pain scores in knee osteoarthritis trials.
-
Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).
This citation reports a human clinical study involving Chondroitin Sulfate. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
4 published studies referenced in the app, each with a plain-language summary.